Home › Prostate Cancer › NCT00969111
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
Recruiting
Postoperative or Salvage Radiotherapy for Node Negative Prostate Cancer Following Radical Prostatectomy
Who can join
Ages 18 and older · Men
Full eligibility criteria
Inclusion Criteria: * Prostate cancer treated primarily with open, laparoscopic or robotically assisted prostatectomy. * Maximum PSA value of 20 ng/ml. Exclusion Criteria: * Evidence of distant metastasis (M1). * Prior systemic chemotherapy for any reason. * Previous irradiation to the pelvis that would compromise the ability to deliver the prescribed study treatment. * Active inflammatory bowel disease (Crohn's disease, diverticulitis or ulcerative colitis) affecting the rectum. (Non-active diverticulitis and Crohn's disease not affecting the rectum are allowed). * Prior or concurrent cancer, other than non-melanomatous skin cancer, unless disease free for at least 5 years. * Taking Saw Palmetto or methotrexate and unable or unwilling to discontinue its use during radiation.
About the study
The purpose of this study is to see what effects, good and/or bad, proton radiation, and/or conventional radiation and hormonal therapy (if applicable), has on prostate cancer that has already returned or the risk of prostate cancer returning.
What is being tested
- IMRT to 45 Gy; prostate bed proton boost of 21.6 CGE (radiation)
- Proton (prostate bed) to 70.2 CGE (radiation)
- IMRT to 45 Gy; proton boost to prostate bed to 25.2 CGE (radiation)
- Proton to 66.6 CGE (radiation)
Sponsor: Proton Collaborative Group · Participants: 70 · Started: 2009-08
Contact the study team
Official record on ClinicalTrials.gov — NCT00969111
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.